Jane Huang Sells 3,000 Shares of Beigene Ltd (NASDAQ:BGNE) Stock

Beigene Ltd (NASDAQ:BGNE) CMO Jane Huang sold 3,000 shares of the company’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $209.93, for a total value of $629,790.00. Following the completion of the transaction, the chief marketing officer now directly owns 326,247 shares of the company’s stock, valued at approximately $68,489,032.71. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Jane Huang also recently made the following trade(s):

  • On Tuesday, July 7th, Jane Huang sold 3,921 shares of Beigene stock. The shares were sold at an average price of $200.00, for a total value of $784,200.00.
  • On Friday, June 26th, Jane Huang sold 2,079 shares of Beigene stock. The shares were sold at an average price of $200.29, for a total value of $416,402.91.
  • On Monday, June 29th, Jane Huang sold 1,935 shares of Beigene stock. The shares were sold at an average price of $190.83, for a total value of $369,256.05.
  • On Monday, June 8th, Jane Huang sold 631 shares of Beigene stock. The shares were sold at an average price of $170.84, for a total value of $107,800.04.
  • On Friday, May 29th, Jane Huang sold 1,500 shares of Beigene stock. The shares were sold at an average price of $163.86, for a total value of $245,790.00.

Shares of NASDAQ:BGNE opened at $209.00 on Friday. The business’s 50 day simple moving average is $202.74 and its two-hundred day simple moving average is $168.21. The firm has a market cap of $18.68 billion, a P/E ratio of -11.85 and a beta of 1.29. The company has a debt-to-equity ratio of 0.08, a quick ratio of 7.89 and a current ratio of 7.96. Beigene Ltd has a 52-week low of $114.41 and a 52-week high of $256.01.

Beigene (NASDAQ:BGNE) last announced its quarterly earnings results on Monday, May 11th. The company reported ($4.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.85) by $0.15. The business had revenue of $52.06 million for the quarter, compared to analyst estimates of $27.00 million. Beigene had a negative return on equity of 68.64% and a negative net margin of 284.45%. On average, equities analysts forecast that Beigene Ltd will post -19.86 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the business. BNP Paribas Arbitrage SA boosted its holdings in Beigene by 208.2% in the first quarter. BNP Paribas Arbitrage SA now owns 28,132 shares of the company’s stock worth $3,463,000 after acquiring an additional 19,005 shares in the last quarter. Aviva PLC boosted its holdings in Beigene by 8.4% in the first quarter. Aviva PLC now owns 16,862 shares of the company’s stock worth $2,076,000 after acquiring an additional 1,304 shares in the last quarter. Royal Bank of Canada boosted its holdings in Beigene by 1.0% in the first quarter. Royal Bank of Canada now owns 18,891 shares of the company’s stock worth $2,325,000 after acquiring an additional 189 shares in the last quarter. HighTower Advisors LLC lifted its holdings in shares of Beigene by 7.4% in the first quarter. HighTower Advisors LLC now owns 28,022 shares of the company’s stock valued at $3,424,000 after purchasing an additional 1,939 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of Beigene by 11.0% in the first quarter. State Street Corp now owns 848,980 shares of the company’s stock valued at $104,518,000 after purchasing an additional 84,190 shares in the last quarter. Institutional investors and hedge funds own 63.78% of the company’s stock.

BGNE has been the subject of several recent research reports. SVB Leerink increased their price target on Beigene from $207.00 to $210.00 and gave the company an “outperform” rating in a research note on Wednesday, June 3rd. Morgan Stanley increased their price target on Beigene from $190.00 to $235.00 and gave the company an “overweight” rating in a research note on Wednesday, July 15th. ValuEngine cut Beigene from a “buy” rating to a “hold” rating in a research note on Thursday, July 2nd. Maxim Group reaffirmed a “buy” rating and set a $250.00 target price (up previously from $190.00) on shares of Beigene in a research note on Friday, July 10th. Finally, BidaskClub cut Beigene from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 24th. Five analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Beigene presently has an average rating of “Buy” and an average price target of $218.13.

Beigene Company Profile

BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Featured Story: What are economic reports?

Insider Buying and Selling by Quarter for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.